A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI-Reference-Cited by-同舟云学术

A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI

Published:2010-11 Issue:12 Volume:18 Page:592-597
ISSN:1568-5888
Container-title:Netherlands Heart Journal
language:en
Short-container-title:Neth Heart J

Author:

Heestermans A.A.C.M.,Hermanides R.S.,Gosselink A.T.M.,de Boer M.J.,Hoorntje J.C.A.,Suryapranata H.,Ottervanger J.P.,Dambrink J-H.E.,Kolkman E.,ten Berg J.M.,Zijlstra F.,van ’t Hof A.W.J.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12471-010-0840-z.pdf

Reference18 articles.

1. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957–966.

2. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759–1765.

3. Nienhuis MB, Ottervanger JP, de Boer MJ, Dambrink JHE, Hoorntje JCA, Gosselink ATM, et al. Zwolle Myocardial Infarction Study Group. Prognostic importance of creatine kinase and creatine kinase-MB after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am Heart J. 2008;155:673–679.

4. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142–154.

5. van ‘t Hof AWJ, ten Berg JM, Heestermans T, Dill T, Funck RC, van Werkum JW, et al. Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537–546.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bailout utilization of tirofiban for distal embolization/acute thrombosis during endovascular management in occlusive PAD patients;Chirurgia;2024-05

2. What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?;Journal of Cardiovascular Pharmacology and Therapeutics;2019-10-23

3. Early Thrombosuction and Tirofiban Use in Knee and Below-Knee Arterial Thrombosis;Medical Science Monitor;2017-04-30

4. Protective Effects of Tirofiban on Myocardial Ischemia–Reperfusion Injury in Rabbits;American Journal of Therapeutics;2016-11

5. Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction;European Heart Journal: Acute Cardiovascular Care;2016-09-22